Table 2.
Efficacy over cycles 2 to 4
| Cycle 2 (week 6) | Cycle 3 (week 6) | Cycle 4 (week 6) | ||||
|---|---|---|---|---|---|---|
| 8U/kg AboBoNT‐A | 16U/kg AboBoNT‐A | 8U/kg AboBoNT‐A | 16U/kg AboBoNT‐A | 8U/kg AboBoNT‐A | 16U/kg AboBoNT‐A | |
| MASPTMG a | n=72 | n=71 | n=35 | n=45 | n=14 | n=23 |
| Mean (SD) at baseline of cycle | 3.1 (0.3) | 3.1 (0.5) | 3.1 (0.4) | 3.1 (0.6) | 3.2 (0.4) | 3.1 (0.3) |
| Mean (SD) change at week 6 | –2.2 (1.0) | –2.3 (1.0) | –2.1 (1.1) | –2.0 (1.2) | –1.6 (1.3) | –1.8 (1.0) |
| n (%) children with ≥1 grade reduction | 65/70 (92.9) | 61/69 (88.4) | 33/35 (94.3) | 40/44 (90.9) | 11/14 (78.6) | 18/20 (90.0) |
| PGA score | n=86 | n=90 | n=45 | n=57 | n=20 | n=33 |
| Mean (SD) score at week 6 | 2.0 (1.0) | 2.0 (1.1) | 2.0 (1.2) | 1.9 (1.1) | 2.1 (0.9) | 1.6 (1.1) |
| n (%) children achieving PGA score ≥1 | 80/85 (94.1) | 83/89 (93.3) | 40/44 (90.9) | 48/56 (85.7) | 20/20 (100.0) | 25/31 (80.6) |
| GAS T score | ||||||
| Mean (SD) score at week 6 | 51.9 (9.5) | 53.4 (9.1) | 49.1 (10.4) | 48.7 (8.7) | 43.7 (8.4) | 48.1 (9.0) |
| n (%) children achieving primary goal (score ≥0) | 64/84 (76.2) | 72/87 (82.8) | 24/45 (53.3) | 39/55 (70.9) | 6/20 (30.0) | 21/31 (67.7) |
a
Children who had the same PTMG throughout the study. AboBoNT‐A, abobotulinumtoxinA; MAS, Modified Ashworth scale; PTMG, primary targeted muscle group; PGA, Physician Global Assessment; GAS, goal attainment scaling.